VIVO Stock Overview
Meridian Bioscience, Inc., a life science company, develops, manufactures, distributes, and sells diagnostic test kits primarily for gastrointestinal and respiratory infectious diseases, and elevated blood lead levels worldwide.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 1/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Meridian Bioscience, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$33.97 |
| 52 Week High | US$34.38 |
| 52 Week Low | US$21.09 |
| Beta | 0.23 |
| 1 Month Change | 2.29% |
| 3 Month Change | 6.02% |
| 1 Year Change | 54.34% |
| 3 Year Change | 295.23% |
| 5 Year Change | 128.75% |
| Change since IPO | 6,030.20% |
Recent News & Updates
Recent updates
Meridian Bioscience Non-GAAP EPS of $0.16 misses by $0.01, revenue of $67.8M beats by $1M
Aug 05Meridian Bioscience: High-Probability Merger Arbitrage
Jul 26Meridian Bioscience downgraded at William Blair on $1.53B acquisition
Jul 07Meridian Bioscience (NASDAQ:VIVO) Has A Pretty Healthy Balance Sheet
Jun 27
Meridian Bioscience: Correctly Valued
Jun 26Many Would Be Envious Of Meridian Bioscience's (NASDAQ:VIVO) Excellent Returns On Capital
Jun 09Meridian Bioscience: Deceptively Priced
Mar 14Meridian Bioscience (NASDAQ:VIVO) Looks To Prolong Its Impressive Returns
Feb 03These 4 Measures Indicate That Meridian Bioscience (NASDAQ:VIVO) Is Using Debt Safely
Jul 19If The COVID-19 Delta Variant Spreads This Fall, Meridian Is Still A Buy
Jul 08Meridian Bioscience (NASDAQ:VIVO) Might Become A Compounding Machine
May 10Meridian Bioscience, Inc. 2021 Q2 - Results - Earnings Call Presentation
May 08Meridian Bioscience (NASDAQ:VIVO) Seems To Use Debt Rather Sparingly
Mar 31Have Insiders Been Buying Meridian Bioscience, Inc. (NASDAQ:VIVO) Shares?
Mar 11Investors Who Bought Meridian Bioscience (NASDAQ:VIVO) Shares A Year Ago Are Now Up 185%
Feb 24Need To Know: Analysts Are Much More Bullish On Meridian Bioscience, Inc. (NASDAQ:VIVO) Revenues
Feb 09
Meridian expands production capacity for COVID-19 tests with NIH funding
Feb 03Should We Be Excited About The Trends Of Returns At Meridian Bioscience (NASDAQ:VIVO)?
Jan 27Does Meridian Bioscience (NASDAQ:VIVO) Deserve A Spot On Your Watchlist?
Jan 13Shareholder Returns
| VIVO | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | 0.06% | -2.9% | -3.1% |
| 1Y | 54.3% | 2.1% | 20.9% |
Return vs Industry: VIVO exceeded the US Medical Equipment industry which returned -3.3% over the past year.
Return vs Market: VIVO exceeded the US Market which returned 14.1% over the past year.
Price Volatility
| VIVO volatility | |
|---|---|
| VIVO Average Weekly Movement | 2.3% |
| Medical Equipment Industry Average Movement | 7.5% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: VIVO has not had significant price volatility in the past 3 months.
Volatility Over Time: VIVO's weekly volatility (2%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1976 | 704 | Jack Kenny | www.meridianbioscience.com |
Meridian Bioscience, Inc., a life science company, develops, manufactures, distributes, and sells diagnostic test kits primarily for gastrointestinal and respiratory infectious diseases, and elevated blood lead levels worldwide. The company operates through Diagnostics and Life Science segments. The Diagnostics segment offers testing platforms, including real-time PCR amplification under the Revogene brand; isothermal DNA amplification under the Alethia brand; lateral flow immunoassay using fluorescent chemistry under the Curian brand; rapid immunoassay under the ImmunoCard and ImmunoCard STAT!
Meridian Bioscience, Inc. Fundamentals Summary
| VIVO fundamental statistics | |
|---|---|
| Market cap | US$1.49b |
| Earnings (TTM) | US$42.46m |
| Revenue (TTM) | US$333.02m |
35.2x
P/E Ratio4.5x
P/S RatioIs VIVO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| VIVO income statement (TTM) | |
|---|---|
| Revenue | US$333.02m |
| Cost of Revenue | US$144.66m |
| Gross Profit | US$188.36m |
| Other Expenses | US$145.90m |
| Earnings | US$42.46m |
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.96 |
| Gross Margin | 56.56% |
| Net Profit Margin | 12.75% |
| Debt/Equity Ratio | 6.8% |
How did VIVO perform over the long term?
See historical performance and comparison